^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    bendamustine

    i
    Other names: SDX-105, SyB L-0501
    Company:
    Generic mfg.
    Drug class:
    DNA replication inhibitor
    Related drugs:
    10d
    EPCORE NHL-2: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (clinicaltrials.gov)
    P1/2, N=543, Active, not recruiting, Genmab | Trial completion date: Sep 2028 --> Sep 2027 | Trial primary completion date: Sep 2028 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    carboplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • vincristine • prednisone • dexamethasone • bendamustine • Epkinly (epcoritamab-bysp)
    11d
    GOLSEEK-2: A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • bendamustine • golcadomide (CC-99282)
    13d
    POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia. (PubMed, Blood Adv)
    This international study evaluated 253 patients receiving frontline fixed-duration bendamustine-rituximab (BR), a common chemoimmunotherapy for WM. In conclusion, BR is effective, irrespective of the MYD88 status, but CXCR4 mutations and POD24 portend worse outcomes. Non-POD24 patients represent a cohort with distinctly favorable outcome.
    Journal • IO biomarker
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Rituxan (rituximab) • bendamustine
    28d
    Primary Breast Lymphoplasmacytic Lymphoma in a Young Woman: A Rare Case of Waldenström's Disease. (PubMed, Cureus)
    The patient was treated with bendamustine-based chemotherapy and corticosteroids, with marked clinical and radiological improvement. This case emphasizes the importance of considering hematologic malignancies in the differential diagnosis of breast lesions to avoid unnecessary surgical management and ensure appropriate systemic therapy.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 negative
    |
    bendamustine
    1m
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations (clinicaltrials.gov)
    P1, N=24, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting | Trial completion date: Feb 2026 --> Jan 2028 | Trial primary completion date: Feb 2026 --> Jan 2028
    Enrollment open • Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    1m
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=150, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • lenalidomide • bendamustine • rocbrutinib (LP-168)
    1m
    BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (PubMed, J Clin Oncol)
    Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.
    P3 data • Journal • IO biomarker
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    Rituxan (rituximab) • Jaypirca (pirtobrutinib) • bendamustine
    1m
    LCCC 1606-ATL: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (clinicaltrials.gov)
    P1, N=43, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2041 --> Nov 2039 | Trial primary completion date: Sep 2026 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CCR4 (C-C Motif Chemokine Receptor 4)
    |
    TNFRSF8 positive • TNFRSF8 expression
    |
    bendamustine • fludarabine IV • TT11 • ATLCAR.CD30.CCR4 cells
    1m
    FIL_V-RBAC: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL (clinicaltrials.gov)
    P2, N=141, Completed, Fondazione Italiana Linfomi - ETS | Active, not recruiting --> Completed
    Trial completion
    |
    CCND1 (Cyclin D1) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • bendamustine
    2ms
    A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • bendamustine • melphalan
    2ms
    ZBR in WM: A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia (clinicaltrials.gov)
    P2, N=43, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • bendamustine
    2ms
    Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2) (clinicaltrials.gov)
    P=N/A, N=222, Completed, University Hospital, Bordeaux | Not yet recruiting --> Completed | Initiation date: Sep 2025 --> Feb 2025
    Trial completion • Trial initiation date
    |
    Adcetris (brentuximab vedotin) • bendamustine